Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.

Zhu X, Zheng L, Asa SL, Ezzat S.

Am J Pathol. 2010 Dec;177(6):2860-9. doi: 10.2353/ajpath.2010.100509. Epub 2010 Oct 29. Retraction in: Am J Pathol. 2015 Aug;185(8):2339.

2.

The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.

Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL.

Cancer Res. 2012 Nov 15;72(22):5683-91. doi: 10.1158/0008-5472.CAN-12-2102. Epub 2012 Sep 17.

3.

Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.

Sugiyama N, Varjosalo M, Meller P, Lohi J, Hyytiäinen M, Kilpinen S, Kallioniemi O, Ingvarsen S, Engelholm LH, Taipale J, Alitalo K, Keski-Oja J, Lehti K.

Cancer Res. 2010 Oct 15;70(20):7851-61. doi: 10.1158/0008-5472.CAN-10-1223. Epub 2010 Sep 28.

4.

Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast.

Dallol A, Buhmeida A, Merdad A, Al-Maghrabi J, Gari MA, Abu-Elmagd MM, Elaimi A, Assidi M, Chaudhary AG, Abuzenadah AM, Nedjadi T, Ermiah E, Alkhayyat SS, Al-Qahtani MH.

Tumour Biol. 2015 Dec;36(12):9677-83. doi: 10.1007/s13277-015-3733-3. Epub 2015 Jul 8.

PMID:
26152288
5.

FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N.

J Clin Oncol. 2006 Aug 10;24(23):3747-55. Epub 2006 Jul 5.

PMID:
16822847
6.

Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site.

Ulaganathan VK, Sperl B, Rapp UR, Ullrich A.

Nature. 2015 Dec 24;528(7583):570-4. doi: 10.1038/nature16449. Epub 2015 Dec 16.

PMID:
26675719
7.

FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.

Stadler CR, Knyazev P, Bange J, Ullrich A.

Cell Signal. 2006 Jun;18(6):783-94. Epub 2005 Aug 18.

PMID:
16109476
8.

Loss of heterozygosity in tumor tissue in hormonal receptor genes is associated with poor prognostic criteria in breast cancer.

Iobagiu C, Lambert C, Raica M, Lima S, Khaddage A, Peoc'h M, Genin C.

Cancer Genet. 2015 Apr;208(4):135-42. doi: 10.1016/j.cancergen.2015.02.007. Epub 2015 Feb 20.

PMID:
25979597
9.

Allelic loss of chromosomal arm 8p in breast cancer progression.

Anbazhagan R, Fujii H, Gabrielson E.

Am J Pathol. 1998 Mar;152(3):815-9.

10.

Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.

Wistuba II, Tomlinson GE, Behrens C, Virmani A, Geradts J, Blum JL, Minna JD, Gazdar AF.

Genes Chromosomes Cancer. 2000 Aug;28(4):359-69.

PMID:
10862044
11.

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province.

Jiang Y, Sun S, Wei W, Ren Y, Liu J, Pang D.

Oncotarget. 2015 Oct 20;6(32):34023-9. doi: 10.18632/oncotarget.5850.

12.

Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.

Borges S, Döppler H, Perez EA, Andorfer CA, Sun Z, Anastasiadis PZ, Thompson E, Geiger XJ, Storz P.

Breast Cancer Res. 2013 Aug 23;15(2):R66. doi: 10.1186/bcr3460.

13.

High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor.

Gupta S, Joshi K, Wig JD, Arora SK.

Indian J Cancer. 2009 Oct-Dec;46(4):303-10. doi: 10.4103/0019-509X.55550.

14.

The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.

Tateno T, Asa SL, Zheng L, Mayr T, Ullrich A, Ezzat S.

PLoS Genet. 2011 Dec;7(12):e1002400. doi: 10.1371/journal.pgen.1002400. Epub 2011 Dec 8.

15.
16.

Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.

Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A.

Cancer Res. 2002 Feb 1;62(3):840-7.

17.

The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.

da Costa Andrade VC, Parise O Jr, Hors CP, de Melo Martins PC, Silva AP, Garicochea B.

Exp Mol Pathol. 2007 Feb;82(1):53-7. Epub 2006 Nov 3.

PMID:
17084840
18.

Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.

Ezzat S, Zheng L, Winer D, Asa SL.

Mol Endocrinol. 2006 Nov;20(11):2965-75. Epub 2006 Jul 20.

PMID:
16857743
19.

Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.

Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stättner S, Karner J, Klimpfinger M, Wrba F, Reti A, Hegedus B, Baierl A, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Cancer Res. 2012 Nov 15;72(22):5767-77. doi: 10.1158/0008-5472.CAN-11-3654. Epub 2012 Sep 12.

20.

FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.

Falvella FS, Frullanti E, Galvan A, Spinola M, Noci S, De Cecco L, Nosotti M, Santambrogio L, Incarbone M, Alloisio M, Calabrò E, Pastorino U, Skaug V, Haugen A, Taioli E, Dragani TA.

Int J Cancer. 2009 Jun 15;124(12):2880-5. doi: 10.1002/ijc.24302.

Supplemental Content

Support Center